- Molecular NameTravoprost
- SynonymNA
- Weight500.554
- Drugbank_IDDB00287
- ACS_NO157283-68-6
- Show 3D model
- LogP (experiment)N/A
- LogP (predicted, AB/LogP v2.0)3.84
- pkaN/A
- LogD (pH=7, predicted)3.84
- Solubility (experiment)N/A
- LogS (predicted, ACD/Labs)(ph=7)-4.87
- LogSw (predicted, AB/LogsW2.0)0.08
- Sw (mg/ml) (predicted, ACD/Labs)0.01
- No.of HBond Donors3
- No.of HBond Acceptors6
- No.of Rotatable Bonds14
- TPSA96.22
- StatusFDA approved
- AdministrationTopical (eye drops)
- PharmacologyA topical medication used for controlling the progression of glaucoma or ocular hypertension, by reducing intraocular pressure.
- Absorption_valueN/A
- Absorption (description)Systemically absorbed when administered to the eye.
- Caco_2N/A
- BioavailabilityN/A
- Protein bindingN/A
- Volume of distribution (VD)N/A
- Blood/Plasma Partitioning ratio (D_blood)N/A
- MetabollsmTravoprost, an isopropyl ester prodrug, is hydrolyzed by esterases in the cornea to its biologically active free acid. Systemically, travoprost free acid is metabolized to inactive metabolites via beta-oxidation of the α(carboxylic acid) chain to give the 1,2-dinor and 1,2,3,4-tetranor analogs, via oxidation of the 15-hydroxyl moiety, as well as via reduction of the 13,14 double bond.
- Half lifeTerminal elimination half-life is 45 minutes (range 17 to 8 minutes).
- ExcretionN/A
- Urinary ExcretionN/A
- CleranceN/A
- ToxicitySymptoms of overexposure include irritation to the skin, eyes, nose, throat, and respiratory tract.
- LD50 (rat)N/A
- LD50 (mouse)N/A